Akcea Announces Appointment of New Chief Operating Officer
“Alex joins our team during an exciting time at Akcea. His decades of experience in the biopharmaceutical sector will further strengthen our executive leadership team and position us to continue to build on our strong record of progress and success. Alex has a background in leading companies as they optimize organizational, commercial and business strategies. His experience aligns well with our goals as we continue to invest in our two commercial-stage products and our promising pipeline of novel drugs positioned to address major areas of unmet need in health in the years ahead,” said Damien McDevitt, Ph.D., Akcea’s interim chief executive officer.
Mr. Howarth has more than 25 years of experience in healthcare and financial advisory roles at various companies. Prior to Akcea, Mr. Howarth served as president at
“I am excited to be joining Akcea and look forward to working with the outstanding leadership team to reach new levels of momentum and success in the company’s business operations. It is an honor to be part of a team committed to bringing transformative treatments to patients globally who suffer from rare and serious diseases and have significant unmet medical needs,” said Mr. Howarth.
ABOUT AKCEA THERAPEUTICS, INC.
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akcea’s drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in Akcea’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.
In this press release, unless the context requires otherwise, “Ionis,” “Akcea,” “Company,” “Companies,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc., Akcea Therapeutics®, TEGSEDI® and WAYLIVRA® are trademarks of Akcea Therapeutics, Inc.
Akcea Investor Contact:
Akcea Media Contact:
T: 212 253-8881
T: 212 253-8881
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/604204a1-7c08-4ff5-bab6-c7adf42fb77c
Source: Akcea Therapeutics, Inc.